Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice and conveys a 4- to 5-fold increased risk of stroke; yet, it often goes undiagnosed and untreated in a primary care setting. In the program, Dr. Ty Gluckman discusses how to recognize patients at high risk for AF, evaluate patients newly diagnosed with AF, assess risk of bleeding and thromboembolism, and apply evidence-based recommendations to reduce thromboembolic risk. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 8/4/2020, and they are subject to change as new information is published.
Episode 2: Bridging the Gap: Conversations with Dr. Hall
This session will provide an overview of the best practices in the treatment of cardiovascular problems in African Americans with a focus on hypertension, heart failure, stroke, vascular disease, arrhythmias, and thrombosis. Overarching trends in salt sensitivity, smoking, and medication adherence will also be reviewed, as well as opportunities to positively impact behavior. Dr. Hall is a Primary Care Physician and an expert in Black American Health and Healthcare. He is the former chair of the Ohio Commission on Minority Health, Director of the National Center for African American Health, Research, Education and Policy at Cleveland State University, and Author of “Patient-Centered Clinical Care for African Americans: A Concise, Evidence-Based Guide to Important Differences and Better Outcomes”. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 08/11/2020 and they are subject to change as new information is published.
Watch distinguished faculty from Northwestern University examine clinical trial data and the latest evidence-based guidelines for hypercholesterolemia to help you develop a practical approach to lipid management for primary care. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on August 12, 2020, and they are subject to change as new information is published.
Heart failure (HF) affects 6.2 million people in the United States, with 1 million new cases occurring annually and a resultant 1 million hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline-recommended diagnosis and management of heart failure. You will learn the essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management.
Join cardiologist Ty Gluckman, MD in part one of this two part podcast series as he reviews the latest guideline-based management of heart failure with reduced ejection fraction (HFrEF), bringing to light major advances in the past years and evidence supporting these advances. Listen to part two of this podcast series here: https://www.pri-med.com/online-education/podcast/gluckman-hf-2
Join cardiologist Ty Gluckman, MD in part two of this two-part podcast series as he reviews the unmet needs of patients with heart failure with reduced ejection fraction (HFrEF) and discusses the evidence on emerging pharmacologic treatments for HFrEF. He will describe the current data in HFrEF for the following drug classes: SGLT2 inhibitors, soluble guanylate cyclase stimulators, and selective cardiac myosin activators.
This initiative aims to increase understanding among cardiologists about adjunctive LDL-C-lowering therapies and their potential role in reducing residual ASCVD risk. During this series, national lipid expert faculty will discuss the incidence of and diagnostic criteria for statin intolerance, explain the mechanistic rationale for lowering LDL-C through nonstatin therapies, and explore novel targets and treatment pathways. It is expected to improve cardiologists’ management of patients with ‘tough-to-treat’ cholesterol according to the 2018 American Heart Association (AHA)/American College of Cardiology (ACC)/Multi-society Cholesterol Guidelines. Learners will have the opportunity to gain practical clinical perspectives during expert case study discussions. The patient scenarios will discuss how new treatment options may fit into the current therapeutic landscape.
As the incidence of diabetes and obesity continue to grow, more Americans will develop serious complications and experience premature mortality from cardiometabolic causes. This session will enable you to stay up to date on recent groundbreaking research and management guideline updates that could change the way you treat your patients with diabetes, obesity, and/or dyslipidemia.
The Top Questions I Most Often Get Asked About: Hypertension, Polypharmacy in the Elderly, and Asthma
What do primary care providers need to know to know about hypertension, polypharmacy in the elderly, and asthma? Join cardiologist Karol Watson, geriatrician Lee Lindquist, and pulmonologist Sunjay Devarajan as they review important questions, they get asked about these three topics! Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/4/2020 and they are subject to change as new information is published.
After implementing current guideline-directed medical management, there is still urgency to address residual cardiovascular risk. Among the drivers of residual cardiovascular risk, inflammation has generated considerable interest, first based on preclinical and biomarker studies in humans. More recently, translation has inspired clinical trials in this domain. This presentation will consider inflammation as a process that links traditional and nontraditional risk factors to atherothrombotic events.
This presentation will review the various effects that COVID-19 may have on the cardiovascular system, with a focus on acute cardiac injury, myocarditis, and arrhythmias.